Ravidasvir

Abstract: Background Chronic hepatitis C virus (HCV) is a worldwide health problem that can lead to liver cirrhosis, liver cell failure and numerous subsequent complications such as hepatocellular carcinoma. Till the near past, pegylated interferon was the standard of care therapy. However, it was associated with suboptimal success rates and many side effects. Thereafter, direct antiviral agents (DAA) appeared and played the key role in management of HCV. One of those recent DAAs is ravidasvir. Summary It is a potent NS5A inhibitor that was formerly known as PPI-668. It is produced by the cooperation of Presidio pharmaceuticals and Pharco International pharmaceutical company. Since its first production, it has been enrolled in different successive clinical trials. Phase 1 and 2 trials confirmed its safety and tolerability and its great efficacy in suppressing viral loads in short periods. It has a pangenotypic activity with favorable pharmacokinetic properties. Ravidasvir inhibits the replication of HCV variants that develop resistance mutations for different DAA classes. Even more, HCV variants that had reduced susceptibility to ravidasvir are completely susceptible to other DAA. Finally, a large multicenteric registrational phase 3 clinical trial that included large percentages of difficult to treat patients (such as cirrhotic and interferon experienced patients) has been fully accomplished and proved great SVR12 rates. Conclusion Ravidasvir is a potent new NS5A inhibitor with excellent safety and tolerability in management of genotype 4 HCV patients.

Abstract: The invention provides a pharmaceutical composition for treatment of viral hepatitis c, wherein the pharmaceutical composition comprises ravidasvir or medicinal salts (ASC16) thereof and danoprevir ormedicinal salts (ASC08) thereof. The combined application of the ASC16 and the ASC08 has enhanced effect. Experimental results show that the ASC16 and the ASC08 can form an effective combined anti-HCV treatment scheme. Moreover, the combined medication scheme of the ASC16 and the ASC08 enlarges the action spectrum of therapeutic drugs. More importantly, the combination of the two components solves the problem of drug resistance.